Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABX203
- Development stage
- Phase 3
- Lead developer
- Abivax
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal, Subcutaneous
01
Overview
ABX203 is a therapeutic vaccine developed for the treatment of chronic hepatitis B virus (HBV) infection. It is composed of two recombinant proteins from HBV—the surface antigen (HBsAg) and the nucleocapsid (core) antigen (HBcAg). The vaccine is designed to induce both neutralizing antibodies against HBsAg and strong cellular immune responses, mimicking those seen in patients who naturally clear acute HBV infection. ABX203 has been formulated for administration as a nasal spray or subcutaneous injection. Clinical trials have shown that it can sustain viral load suppression for at least six months after cessation of therapy, potentially offering advantages over standard treatments such as nucleos(t)ide analogues and pegylated interferon alpha[5][4][1]. The drug was originally developed by the Center for Genetic Engineering and Biotechnology in Cuba, with further development and commercialization rights licensed to Abivax.
- Brand names
- HeberNasvac
- Other names
- HeberNasvac
02
Targets
HBc (Hepatitis B virus core protein)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on ABX203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABX203.